MicroRNA-targeting therapeutics for hepatitis C
- Authors
- Baek, Jihae; Kang, Soowon; Min, Hyeyoung
- Issue Date
- Mar-2014
- Publisher
- PHARMACEUTICAL SOC KOREA
- Citation
- ARCHIVES OF PHARMACAL RESEARCH, v.37, no.3, pp 299 - 305
- Pages
- 7
- Journal Title
- ARCHIVES OF PHARMACAL RESEARCH
- Volume
- 37
- Number
- 3
- Start Page
- 299
- End Page
- 305
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12412
- DOI
- 10.1007/s12272-013-0318-9
- ISSN
- 0253-6269
1976-3786
- Abstract
- MiR-122 is a liver-specific microRNA (miRNA) that plays a pivotal role in regulating hepatic functions such as lipid metabolism and stress response. The observation that hepatitis C virus (HCV) could only replicate in miR-122-positive hepatocytes led to the discovery that miR-122 is essential for HCV replication, and miR-122 is now one of the crucial host factors for anti-HCV therapy. Currently, the most advanced miR-122 targeting therapy is SPC3649 (miravirsen), a locked nucleic acid-modified oligonucleotide antagonizing miR-122. This review serves to provide information on the discovery and development of SPC3649, the first miRNA-targeted drug to enter human clinical trials, and introduce other miR-122-targeting therapeutics being developed for hepatitis C.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12412)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.